Search Results for "prophylaxis"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for prophylaxis. Results 191 to 200 of 202 total matches.
Drugs for Stable Angina Pectoris
The Medical Letter on Drugs and Therapeutics • Dec 09, 1994 (Issue 937)
.
The therapeutic effect lasts for less than an hour, making it unsuitable for long-term prophylaxis ...
Many nitrates, beta-blockers, and calcium-channel blockers have now been approved by the US Food and Drug Administration for treatment of stable angina pectoris. The table beginning on page 112 lists the individual drugs, their dosage, and their cost.
Primary Prevention of Ulcers in Patients Taking Aspirin or NSAIDs
The Medical Letter on Drugs and Therapeutics • Mar 08, 2010 (Issue 1333)
, placebocontrolled trial. Lancet 2009; 374:119.
5. D Cullen et al. Primary gastroduodenal prophylaxis ...
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of peptic ulcer disease. Patients infected with Helicobacter pylori who take aspirin or another NSAID have an especially high risk. Drugs that have been tried for prevention of ulcers in patients taking NSAIDs including H2-receptor antagonists, proton pump inhibitors (PPIs), aluminum- or magnesium-containing antacids, the prostaglandin misoprostol (Cytotec, and others), and antibiotics to eradicate H. pylori.Click here to view the free full...
Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
Caserta et al. Palivizumab prophylaxis in infants and young
children at increased risk of hospitalization ...
The FDA has approved nirsevimab-alip (Beyfortus –
AstraZeneca/Sanofi), a long-acting monoclonal
antibody, for the prevention of respiratory syncytial
virus (RSV) lower respiratory tract disease in
neonates and infants born during or entering their
first RSV season, and in children ≤24 months old who
are at increased risk for severe RSV disease through
their second RSV season. Nirsevimab is the first drug
to be approved for protection of all infants during
their first RSV season.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):145-7 doi:10.58347/tml.2023.1685a | Show Introduction Hide Introduction
Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025 (Issue 1725)
not contain alcohol
Other Indications:
▶ Prescription product is also approved for
prophylaxis of seasonal ...
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
Med Lett Drugs Ther. 2025 Mar 31;67(1725):e58-63 doi:10.58347/tml.2025.1725c | Show Introduction Hide Introduction
Drugs for Epilepsy
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
-approved for migraine prophylaxis and, as part of a fixed-dose combination with phentermine (Qsymia ...
When used for the appropriate seizure type,
antiseizure medications (ASMs) are roughly
equivalent in efficacy. In addition to the seizure type,
the choice of drug is usually based on factors such
as ease of use, spectrum of activity, adverse effects,
interactions with other drugs, presence of comorbid
conditions, suitability for elderly persons and those
with childbearing potential, and cost. Treatment
should begin with a single drug, increasing the
dosage gradually until seizures are controlled or
adverse effects become unacceptable. If seizures
persist, expert clinicians generally...
Med Lett Drugs Ther. 2024 Aug 5;66(1708):121-8 doi:10.58347/tml.2024.1708a | Show Introduction Hide Introduction
Drugs of Choice for Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • Mar 31, 1995 (Issue 945)
: Vincristine + prednisone +
asparaginase + daunorubicin or doxorubicin
± cyclophosphamide
CNS prophylaxis ...
Cannabis and Cannabinoids
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019 (Issue 1585)
) despite optimal
prophylaxis with conventional antiemetic drugs such
as palonosetron (Aloxi, and others ...
Cannabis (marijuana) contains more than 60
pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
are the best known. THC is the main psychoactive
constituent of cannabis. CBD, unlike THC, does not
produce intoxication or euphoria.
Drugs of Choice for Cancer
Treatment Guidelines from The Medical Letter • Mar 01, 2003 (Issue 7)
prophylaxis: Intrathecal methotrexate or etoposide; high-dose cytarabine + mitoxantrone;
(± intrathecal ...
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer...
Cardiovascular Drugs in the ICU
Treatment Guidelines from The Medical Letter • Dec 01, 2002 (Issue 4)
, was
frequently used for prophylaxis of ventricular arrhythmias during and after myocardial infarction ...
Ever-increasing specialization has made it difficult for many physicians to keep up with therapeutic standards in intensive-care units (ICUs). This issue of Treatment Guidelines offers current recommendations for use of cardiovascular drugs in the ICU for treatment of hypertensive emergencies; shock, cardiac arrest or decompensated heart failure; and ventricular arrhythmias.
Drugs for Hepatitis C Virus Infection
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
receiving HIV pre-exposure prophylaxis.
Antibody tests can produce false-negative results ...
About 2.5 million persons in the US had hepatitis C
between 2017 and 2020. Guidelines from the American
Association for the Study of Liver Diseases (AASLD)
and the Infectious Diseases Society of America (IDSA)
on management of hepatitis C virus (HCV) infection
were updated in 2023.
Med Lett Drugs Ther. 2024 Oct 28;66(1714):169-74 doi:10.58347/tml.2024.1714a | Show Introduction Hide Introduction
